DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Ruxolitinib in Patients With Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Ruxolitinib

First Posted Date: 2012-03-26

Last Posted Date: 2017-02-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 21

Registration Number: NCT01562873

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Fulvestrant
Drug: Ganetespib

First Posted Date: 2012-03-22

Last Posted Date: 2025-02-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 50

Registration Number: NCT01560416

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
New Hampshire Oncology and Hematology, P.A., Concord, New Hampshire, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

Phase 2

Terminated

Conditions: Melanoma

Interventions: Drug: STA-9090

First Posted Date: 2012-03-13

Last Posted Date: 2017-04-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 3

Registration Number: NCT01551693

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL

Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2012-02-01

Last Posted Date: 2024-07-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 22

Registration Number: NCT01523977

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸
UCSF, San Francisco, California, United States

and more 5 locations

Study of Vitamin D in Untreated Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: FOLFOX + bevacizumab
Dietary Supplement: Vitamin D

First Posted Date: 2012-01-24

Last Posted Date: 2022-04-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 139

Registration Number: NCT01516216

Locations: 🇺🇸
Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States
🇺🇸
Lowell General Hospital, Lowell, Massachusetts, United States
🇺🇸
Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital, South Weymouth, Massachusetts, United States

and more 13 locations

The Preoperative Health & Body Study

Not Applicable

Active, not recruiting

Conditions: Breast Cancer

Interventions: Behavioral: Exercise
Behavioral: Surgical preparation program

First Posted Date: 2012-01-24

Last Posted Date: 2024-10-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 49

Registration Number: NCT01516190

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Socialization of Adult Men With Congenital Hemophilia A or B

Completed

Conditions: Hemophilia A
Hemophilia B

First Posted Date: 2012-01-16

Last Posted Date: 2016-08-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 27

Registration Number: NCT01510418

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: HKI-272
Procedure: Surgical Resection
Drug: Capecitabine
Drug: Ado-Trastuzumab Emtansine

First Posted Date: 2011-12-19

Last Posted Date: 2025-03-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 140

Registration Number: NCT01494662

Locations: 🇺🇸
University of North Carolina at Chapel Hill - Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
UPMC Passavant Cranberry, Cranberry Township, Pennsylvania, United States

and more 15 locations

Dasatinib in Advanced Squamous Cell Lung Cancer

Phase 2

Terminated

Conditions: Squamous Cell Lung Cancer

Interventions: Drug: Dasatinib

First Posted Date: 2011-12-14

Last Posted Date: 2014-07-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT01491633

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma

Phase 2

Terminated

Conditions: Thrombocytopenia
Multiple Myeloma

Interventions: Drug: Eltrombopag

First Posted Date: 2011-12-02

Last Posted Date: 2017-03-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 1

Registration Number: NCT01484314

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy